Astellas Transfers Compounds To DNDi For Drug Discovery In Chagas, Leishmaniasis and Sleeping Sickness
This article was originally published in PharmAsia News
Executive Summary
Astellas and other Japanese pharma have become more open to new partnerships that expand drug access, as well as their market footprint.